Vif determines the requirement for CBF-β in APOBEC3 degradation
Rokusuke Yoshikawa(Nagasaki University), Kei Sato(University of Tokyo Hospital), Fengrong Ren(Tokyo Medical and Dental University), Hiroshi Tanaka(Hachinohe Gakuin University), Reuben S. Harris(The University of Texas at San Antonio Health Science Center), Carsten Münk(Heinrich Heine University Düsseldorf), Yusuke Nakano(Kyoto University), Takayuki Miyazawa(Kyoto Research Park), Junko S. Takeuchi(Institute for Security Studies), Eri Yamada(Hikone Central Hospital), Yoshio Koyanagi(Daido Steel (Japan))
Cited by 16
Related Papers
SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant
|Cell Reports|2020|438
APOBEC3 Proteins Inhibit Human LINE-1 Retrotransposition
|Journal of Biological Chemistry|2006|356